4 Dmt Appoints Uneek Mehra As Chief Financial and Business

Sep 12, 2023•over 2 years ago

Company

4D Molecular Therapeutics

EmeryvilleGeneticsTherapeuticsHealth CareBiotechnology

Description

EMERYVILLE, Calif., Sept. 12, 2023 -- 4D Molecular Therapeutics , a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT. Mr

Company Information

Company

4D Molecular Therapeutics

Location

Emeryville, California, United States

About

4DMT is a late-stage biotechnology company developing durable, disease-targeted genetic medicines designed to transform treatment paradigms and deliver long-lasting benefits to patients. Its lead candidate, 4D-150, aims to become a backbone therapy for blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF agents through a single intravitreal injection, with Phase 3 development underway for wet age-related macular degeneration and a second indication in diabetic macular edema. The company’s second candidate, 4D-710, is the first known genetic medicine to achieve successful aerosol-based delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months